Saratov JOURNAL of Medical and Scientific Research

Chronic obstructive pulmonary disease and cardiovascular risk in terms of nutritional status (review)


Comorbidity risk factors in chronic obstructive pulmonary disease (COPD) is largely determined by the systemic effects of chronic inflammation. Individual phenotypes of the disease have different prognostic significance. The review presents an analysis of literature data about cardiovascular risk in COPD, depending on the nutritional status of a patient. Literature sources were searched using PubMed, CyberLeninka, MedLine, Global Health, eLibrary, Google Scholar databases on queries: comorbidity with COPD, systemic inflammation and COPD, cardiovascular pathology and COPD, obesity and weight deficiency with COPD. The work includes 40 literature sources over the past 10 years on the risk factors of comorbidity in view of systemic inflammation. Four works from an earlier period were also used, demonstrating fundamental and historical information from the point of view of the authors. As a result of the search, the factors of the worst prognosis in COPD patients with weight deficiency and the protective sense of obesity are clarified. This effect allows you to personalize dietary recommendations. Nevertheless, there are not enough data about mechanisms of chronic inflammation with weight deficiency.

1. Global Initiative for Chronic Obstructive Lung Disease: Global Strategy for the Diagnosis, Management, and Prevention of Chronic Obstructive Pulmonary Disease: Revised 2020. URL:
2. Blanco I, Diego I, Bueno P, et al. Geographic distribution of COPD prevalence in the world displayed by geographic information system maps. Eur Respir J 2019; 54(1): 1900610.
3. Charlson M, Pompei P, Ales K, et al. A new method of classifying prognostic comorbidity in longitudinal studies: development and validation. J Chronic Dis 1987; 40: 373-83.
4. Li C, Lin M, Chen P, et al. Using the BODE index and comorbidities to predict health utilization resources in chronic obstructive pulmonary disease. Int J Chron Obstruct Pulmon Dis 2020; 15:389-95.
5. Smith M, Wrobel J. Epidemiology and clinical impact of major comorbidities in patients with COPD. Int Journal of Chron Obstruct Pulmon Dis 2014; 9 (1): 871-88.
6. Vanfleteren L, Spruit M, Groenen M, et al. Clusters of comorbidities based on validated objective measurements and systemic inflammation in patients with chronic obstructive pulmonary disease. Am J Respir Crit Care Med 2013; 187 (7): 728-35.
7. Skotnikov AS, Dokhova OM, Shulgina ES. Systemic inflammation and complications of "vascular" comorbidity in COPD patients. The Russian Archives of Internal Medicine 2015; 5 (25): 49-54.
8. Ovcharenko SI, Nersesyan ZN. Systemic inflammation and endothelial dysfunction in patients with chronic obstructive pulmonary disease in combination with hypertension: review of the literature and our own data. Consilium Medicum 2015; 17 (11): 8-12.
9. Uryasyev ОМ, Panfilov YuA, Granatkin MA, et al. Chronic obstructive pulmonary disease and comorbidity. Journal of Volgograd State Medical University 2020; 2 (74): 174-7.
10. Aisanov ZR, Avdeev SN, Arkhipov VV, et al. National clinical recommendation on COPD. Pulmonology 2017; 27 (1): 13-20.
11. Mamaeva MG, Demko IV, Verigo Yal, et al. Markers of systemic inflammation and endothelial dysfunction in patients with chronic obstructive pulmonary disease. Siberian Medical Review 2014; (1): 12-9.
12. Barbu С, lordache М, Man М. Inflammation in COPD: pathogenesis, local and systemic effects. Rom J Morphol Embriol 2011; 52(1): 21-7.
13. Bagdonas E, Raudoniute J, et al. Novel aspects of pathogenesis and regeneration mechanisms in COPD. Int J Obstruct Pulmon Dis2015; 10:995-1013.
14. Cho W-K, Lee G, Kim L. COPD as a disease of immunosenescence. Yonsei Med J 2019; 60 (5): 407-13.
15. Singh S, Verma SK, Kumar S, et al. Correlation of severity of chronic obstructive pulmonary disease with potential biomarkers. Immunol Lett 2018; 196: 1-10.
16. Budnevskiy AV, Malysh EYu Chronic obstructive lung disease as risk factor for cardiovascular disorders. Cardiovascular Therapy and Prevention 2016; 15 (3): 69-73.
17. Lahousse L, Loth D, Joos G, et al. Statins, systemic inflammation and risk of death in COPD: the Rotterdam study. Pulm Pharmacol Ther 2013; 26 (2): 212-7.
18. Kostenko DYu, Zaykova-Khelimskaya IV. Chronic obstructive pulmonary disease: attention to exacerbation of disease. Far East Medical Journal 2019; (4): 97-100.
19. Walter R, Wilk J, Larson M, et al. Systemic inflammation and COPD: the Framingham Heart Study Chest 2008; 133 (1): 19-25.
20. Ignatova GL, Antonov VN. Prognostic indices and markers of systemic inflammation in patients with COPD and CAD. Medical Council 2017; (4): 81-5.
21. Constans J, Conri С. Circulating markers of endothelial function in cardiovascular disease. Clinica Chimica Acta 2006; 368: 33-47.
22. Filley G, Beckwitt H, Reeves J, et al. Chronic obstructive bronchopulmonary disease: Oxygen transport in two clinical types. Am J Med 1968; 44: 26-38.
23. Nikitin AV, Vasilieva LV, Karpukhina EP, et al. Historical classification of COPD. Tuberculosis and Lung Diseases 2018; 96 (1): 51-6.
24. Afshin A, Forouzanfar M, Reitsma M, et al. Health effects of overweight and obesity in 195 countries over 25 years. N Engl J Med 2017; 377 (1):13-27.
25. Costanzo P, Cleland J, Pellicori P, et al. The obesity paradox in type 2 diabetes mellitus: relationship of body mass index to prognosis: a cohort study. Ann Intern Med 2015; 162 (9): 610-18.
26. Curtis J, Selter J, Wang Y, et al. The obesity paradox: body mass index and outcomes in patients with heart failure. Arch Intern Med 2005; 165 (1): 55-61.
27. Faletrova SV, Korshunova LV, Belskikh ES. Clinical and functional features of chronic obstructive lung disease in patients with obesity. Eruditio Juvenium 2018; 6 (3): 439-47.
28. Huber М, Kurz Ch, Kirsch F, et al. The relationship between body mass index and health-related quality of life in COPD: real-world evidence based on claims and survey data. Respir Res 2020; 21: 291.
29. Szucs B, Szucs C, et al. Molecular characteristics and treatment of endothelial dysfunction in patients with COPD: a review article. Int J Mol Sci 2019; 20: 4329.
30. Yang L, Zhu Y, Huang J-A, et al. A low lean-to-fat ratio reduces the risk of acute exacerbation of chronic obstructive pulmonary disease in patients with a normal or low body mass index. Med Sci Monit 2019; 25: 5229-36.
31. Putcha N, Anzueto A, Calverley P, et al. Mortality and exacerbation risk by body mass index in patients with COPD in TIOSPIR and UPLIFT. Ann Am Thorac Soc 2021; Aug 18.
32. Zhu J, Zhao Zh, Wu B, et al. Effect of body mass index on lung function in Chinese patients with chronic obstructive pulmonary disease: a multicenter cross-sectional study. Int J Chron Obstruct Pulmon Dis 2020; 15: 2477-86.
33. Lainscak M, Von Haehling S, Doehner W, et al. Body mass index and prognosis in patients hospitalized with acute exacerbation of chronic obstructive pulmonary disease. J Cachexia Sarcopenia Muscle 2011; 2 (2): 81-6.
34. Guo Y, Zhang T, Wang Zh, et al. Body mass index and mortality in chronic obstructive pulmonary disease. Medicine (Baltimore) 2016; 95 (28): e4225.
35. Nguyen H, Collins P, Pavey T. Nutritional status, dietary intake, and health-related quality of life in outpatients with COPD. Int J of COPD 2019; 14: 215-26.
36. Ingadottir A, et al. Oral nutrition supplements and between-meal snacks for nutrition therapy in patients with COPD identified as at nutritional risk: a randomised feasibility trial COPD. BMJ Open Resp Res 2019; 6: e000349.
37. Klooster K, Hacken N, Hartman J, et al. Determining the role of dynamic hyperinflation in patients with severe chronic obstructive pulmonary disease. Respiration 2015; 90 (4): 306-13.
38. Rondanelli M, Faliva M, Peroni G. Food pyramid for subjects with COPD. Int J of COPD 2020; 15: 1435-48.
39. Kobylyanskiy VI. Contrinsulinar hormons in glucose homeostase and in diabetus mellitus pathogenesis in COPD. Problems of Endocrinology 2021; 67 (2): 93-101.
40. Mete В, Pehlivan Е, Gulbas G, et al. Prevalence of malnutrition in COPD and its relationship with the parameters related to disease severity. Int J Ch Obstr Pulm Dis 2018; 13: 3307-12.
41. Maclay J, McAllister D, Rabinovich R, et al. Systemic elastin degradation in chronic obstructive pulmonary disease. Thorax 2012; 67 (7): 606-12.
42. Shchupakova AN, Okulich AN, Belyaeva LE, et al. Proteolitic activities of neutrofils elastase in cardiovascular pathology prognosis. Journal of Volgograd State Medical University 2016; 15 (2): 17-26.
43. Brodskaya ТА, Nevzorova VA, Vasileva MS, et al. Endothelium-related and neuro-mediated mechanisms of emphysema development in chronic obstructive pulmonary disease. Therapeutic Archive 2020; 92 (3): 116-24.
44. Chaulin AM, Duplyakov DV Comorbidity in chronic obstructive pulmonary disease and cardiovascular disease. Cardiovascular Therapy and Prevention 2021; 20 (3): 91-9.

2021_03-1_553-559.pdf325.24 KB

No votes yet